News

Domestic development of autologous skeletal muscle-derived cells (ICEF15) targeting fecal incontinence is finally underway.

The clinical trial application for a Phase III study of autologous skeletal muscle-derived cells (ICEF15) targeting fecal incontinence has been submitted.

The first administration to a patient in the Phase III trial of autologous skeletal muscle-derived cells (ICEF15) targeting fecal incontinence has been completed.

Innovacell has obtained the ‘Certification for Specific Cell Processing Products’ (Facility Number: FB8220003) from the Ministry of Health, Labour and Welfare based on the Act on Securing Safety etc. of Regenerative Medicine.

Results of the Phase IIb clinical trial of ICEF15 have been published in the American journal Clinical Gastroenterology and Hepatology.

Closed Series C funding, raising a total of 2.7 billion yen.

Completed the withdrawal of €15 million (approximately 2.1 billion yen) from the European Investment Bank Venture Debt.

Completed a fundraising of 550 million yen from HiJoJo Partners and others.

Enrollment of Patients for Phase III Trial of Autologous Skeletal Muscle-Derived Cells (ICEF15) for Fecal Incontinence Has Begun

Fundraising of 700 Million Yen from Fiducia and Yokohama Capital